Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > IBRX taking a beating today...

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Apr 24, 2024 9:33pm

206 Views

Post# 36006306

RE:RE:IBRX taking a beating today...

The IBRX write up specifically mentions 3 doctors from UBC giving great credits to the Anktiva treatment and suggesting it could become the new BCG standard.

I thought Theralase had UBC as a study site? Would these same doctors also be working with the TLT study? Or would they be completely separate?

Or was UBC dropped from the TLT study centers? This headline below shows UBC being added but I do not see anything saying it was dropped.